Kaposi Sarcoma and HIV in Zimbabwe: Symptoms, Treatment & Options in India 2025

Kaposi sarcoma is Zimbabwe's most common cancer in men, yet most cases are misdiagnosed for months. Learn the symptoms on dark skin, the HIV connection, what treatment exists in Zimbabwe, and how Zimbabwean patients access complete KS care in India.

Blessing noticed the marks on his legs in February.

He was 39, a mechanic in Chitungwiza, and he had been living with HIV for six years. His viral load was well-controlled on antiretroviral therapy. He felt well. The marks — dark purple, slightly raised, painless — appeared on his lower legs and seemed to be spreading slowly.

He assumed it was a skin infection. He bought a cream from the pharmacy. The marks did not go away. Two months later, more had appeared — on his upper body, and one on his face near his jawline.

His wife insisted he go to the clinic. The nurse who examined him recognised the lesions immediately and referred him, urgently, to Parirenyatwa Hospital.

The diagnosis was Kaposi sarcoma. Stage three — widespread skin involvement with early visceral disease.

Blessing had been looking at those marks for four months and had not known what they were. He is not unusual. Across Zimbabwe, Kaposi sarcoma is simultaneously one of the most common cancers and one of the most poorly understood — by patients, by families, and in many cases by the primary care workers who are often the first to see it.

This article changes that.

---

What Is Kaposi Sarcoma?

Kaposi sarcoma — abbreviated KS — is a cancer that originates in the cells lining blood vessels and lymphatic vessels. It was first described in 1872 by a Hungarian dermatologist named Moritz Kaposi, and for most of its history it was considered a rare, slow-moving disease primarily affecting elderly men of Mediterranean or Eastern European descent.

Then the HIV epidemic changed everything.

In the 1980s, Kaposi sarcoma emerged as one of the defining features of AIDS — appearing in HIV-positive individuals whose immune systems had been severely compromised, progressing rapidly, and claiming lives with a speed that the pre-AIDS version of the disease rarely showed. It became one of the first clinical signals that the AIDS epidemic had arrived.

In Zimbabwe today, KS is the most common cancer among Zimbabwean men and one of the leading causes of cancer death overall. It is also among the most common cancers in children, where it manifests as lymph node disease rather than the skin lesions seen in adults.

Understanding Kaposi sarcoma in Zimbabwe requires understanding the relationship between KS, HIV, and a third key player — a virus that most people have never heard of.

---

The Three-Way Relationship: KS, HIV, and KSHV

Kaposi sarcoma is not caused directly by HIV. It is caused by a separate virus — Kaposi Sarcoma Herpesvirus (KSHV), also known as Human Herpesvirus 8 (HHV-8).

KSHV is extremely common in sub-Saharan Africa. Population studies suggest that 30 to 60% of adults in Zimbabwe carry KSHV — compared to 1 to 5% of adults in Western Europe or North America. Most people who carry KSHV never develop Kaposi sarcoma. The immune system keeps the virus in check indefinitely.

This is where HIV enters the picture.

HIV progressively destroys CD4 cells — the immune cells that act as the body's surveillance and defence system. As CD4 counts fall, the immune system loses its ability to suppress KSHV. The virus activates, spreads, and transforms the lining cells of blood vessels into cancer cells — producing the characteristic lesions of KS.

This is why KS is so closely linked to HIV in Zimbabwe: not because HIV causes KS directly, but because HIV creates the immune environment in which KSHV — already widely present in the population — can finally act.

The implication is important. A Zimbabwean man or woman living with HIV and carrying KSHV is at ongoing risk of Kaposi sarcoma — particularly if their HIV is not well-controlled, if their CD4 count has dropped significantly at any point, or if antiretroviral therapy is interrupted.

This risk does not disappear with effective HIV treatment. It reduces substantially — but it does not go to zero. Zimbabweans living with HIV need to know what Kaposi sarcoma looks like, because they are in the group most likely to see it.

---

The Four Types of Kaposi Sarcoma

Not all Kaposi sarcoma is the same. Understanding the different types helps make sense of who is affected and how the disease behaves.

Classic KS affects elderly men, typically of Mediterranean, Eastern European, or Jewish descent. It is slow-growing, primarily affects the skin of the lower legs, and rarely spreads to internal organs. This is the form Moritz Kaposi originally described. It is not common in Zimbabwe.

African endemic KS affects younger adults and children across sub-Saharan Africa — including Zimbabwe — and existed in the region before the HIV epidemic. It is more aggressive than classic KS, can involve lymph nodes and internal organs even in HIV-negative individuals, and is more common in areas of high KSHV prevalence. It is this form of KS that was already present in Zimbabwe before HIV arrived.

AIDS-related KS (epidemic KS) is by far the most common form in Zimbabwe today. It occurs in people living with HIV whose immune systems are compromised. It can be widespread, rapid, and life-threatening. It affects the skin, lymph nodes, oral cavity, lungs, gut, and liver. The faster and more complete the immune collapse, typically the more aggressive the KS.

Iatrogenic KS occurs in people whose immune system has been deliberately suppressed — for example, transplant patients taking immunosuppressive medications. This form is not commonly seen in Zimbabwe but is worth understanding as solid organ transplantation becomes more accessible in the region.

---

Who Is at Risk in Zimbabwe?

Kaposi sarcoma risk in Zimbabwe is strongly shaped by two factors: HIV status and KSHV infection.

People living with HIV are the primary at-risk population in Zimbabwe. The lower the CD4 count — the more immunocompromised a person is — the higher the risk. People who have experienced prolonged periods of low CD4 counts, or whose HIV was diagnosed late and therefore spent years uncontrolled, carry the highest KS risk.

This does not mean KS only affects people with advanced AIDS. With widespread antiretroviral therapy access in Zimbabwe, many people living with HIV have good CD4 counts — and KS can still occur even at CD4 counts above 200. Regular monitoring is essential.

Men are more affected than women with AIDS-related KS in Zimbabwe, though the gap is narrowing as HIV treatment reaches more people across all demographics.

Children with HIV — particularly those with high viral loads and low CD4 counts — are at risk of the lymph node form of KS, which is the most common childhood cancer presentation in parts of sub-Saharan Africa.

HIV-negative people can develop African endemic KS, though this is less common. If you are HIV-negative and develop unexplained skin lesions of the type described below, KS is still a possibility worth investigating — particularly given the high KSHV prevalence in Zimbabwe.

---

Recognising Kaposi Sarcoma: What to Look For

The most recognisable feature of Kaposi sarcoma is its skin lesions — but not everyone knows what those lesions look like, and they are frequently misidentified.

Skin Lesions

KS skin lesions typically appear as:

Flat or slightly raised patches on the skin that are pink, red, purple, or dark brown in colour. On darker skin — the skin of most Zimbabwean patients — the lesions often appear darker than the surrounding skin, ranging from deep purple to nearly black. This is a critically important point: on black skin, KS lesions are frequently missed or misidentified because the colour contrast is less dramatic than in the textbook images developed for lighter skin tones.

The lesions are typically painless in early stages — which is one reason they are dismissed. They do not itch, they do not blister, and they do not feel like the infected skin conditions most people associate with something requiring medical attention.

They can appear anywhere on the body — though the legs, feet, face, and trunk are common sites. Oral lesions — on the palate, gums, or tongue — are found in a significant proportion of AIDS-related KS cases.

Over time, lesions may grow, merge, thicken, and become nodular. In advanced disease, surrounding tissue can become swollen from lymphatic involvement, and lesions can break down, ulcerate, and become painful.

Internal and Systemic KS

Kaposi sarcoma frequently affects internal organs — particularly the lungs, gut, and lymph nodes — either alongside skin lesions or, less commonly, without obvious skin involvement.

Pulmonary KS — involvement of the lungs — presents with shortness of breath, cough, and sometimes coughing up blood. It is a serious form of KS that is frequently misdiagnosed as tuberculosis or pneumonia.

Gastrointestinal KS can cause abdominal pain, diarrhoea, nausea, rectal bleeding, and difficulty swallowing if the oesophagus is involved. It is often found incidentally during endoscopy for other reasons.

Lymph node KS causes swollen, enlarged lymph nodes and significant oedema — swelling of the limbs, particularly the legs and face — from lymphatic obstruction.

Oral KS — lesions in the mouth — can interfere with eating, cause dental problems, and spread to the throat.

This internal involvement is why Kaposi sarcoma is not simply a skin disease. It is a systemic cancer that happens to most visibly manifest on the skin.

---

Diagnosis: How Kaposi Sarcoma Is Confirmed

A clinical diagnosis — recognising KS from the appearance of lesions — is often made by experienced clinicians in high-prevalence settings. But confirmation requires histopathology.

Skin biopsy is the standard diagnostic procedure. A small sample of a skin lesion is taken under local anaesthesia and examined under a microscope. The characteristic appearance of KS — spindle cells, abnormal blood vessel formation, and KSHV-positive cells confirmed by immunohistochemistry — confirms the diagnosis.

HIV testing and CD4 count — if not already known — are essential components of the workup for any suspected KS case. CD4 count and viral load determine both the treatment urgency and the management of the underlying HIV.

Staging assessment — to determine whether KS has spread beyond the skin — typically includes:

Endoscopy (upper and lower) to assess GI involvement. This is important because GI KS may be present without symptoms and its presence changes staging.

Chest X-ray or CT scan of the chest to assess pulmonary involvement.

CT scan of the abdomen and pelvis to assess lymph node and organ involvement.

In Zimbabwe, the staging workup is often incomplete — not because oncologists do not know what is needed, but because imaging availability and endoscopy access are limited outside the main hospitals. This means visceral involvement is sometimes missed, and staging is sometimes less accurate than international guidelines recommend.

---

Treatment: What Zimbabwe Offers and Where the Gaps Are

Antiretroviral Therapy — The Foundation of KS Treatment

For AIDS-related KS in HIV-positive patients, optimising antiretroviral therapy (ART) is the single most important treatment intervention. When HIV is controlled and CD4 counts recover, the immune system can suppress KSHV and, in a proportion of patients with limited disease, KS lesions regress without any additional cancer-specific treatment.

In Zimbabwe, ART coverage has expanded substantially over the past two decades. For patients who are already on ART when KS is diagnosed, the first step is ensuring viral suppression — confirming that the regimen is effective and the patient is adherent.

For patients not yet on ART, initiating treatment promptly is a priority.

ART-driven immune reconstitution can result in complete or partial KS remission in patients with limited skin-only disease. For patients with extensive skin involvement, lymph node disease, or visceral disease, additional treatment is required.

Chemotherapy for KS

Liposomal doxorubicin (Doxil/Caelyx) — pegylated liposomal doxorubicin — is the internationally recommended first-line chemotherapy for advanced AIDS-related KS. It is more effective and less toxic than older KS chemotherapy regimens and is considered standard of care by WHO and international oncology guidelines.

Its availability in Zimbabwe's public system is inconsistent. At times it has been available through specific treatment programmes at Parirenyatwa and Mpilo. At other times, it is unavailable, and patients are treated with older alternatives.

Paclitaxel is a second-line chemotherapy agent for KS that has not responded to liposomal doxorubicin. It is available at some facilities in Zimbabwe but access is not reliable.

Vincristine, bleomycin, and doxorubicin (AVB) — an older combination regimen — is sometimes used when preferred agents are unavailable. It is less effective and carries higher toxicity.

Radiotherapy for KS

Local radiotherapy — directed at specific skin lesions or lymph node masses — can provide effective palliation for KS lesions that are causing cosmetic distress, pain, or functional problems. It does not treat systemic disease.

In Zimbabwe, radiotherapy for KS is available at the two main treatment centres but is subject to the same machine availability issues that affect all radiotherapy in the country.

What Zimbabwe Cannot Reliably Offer

Reliable, continuous access to liposomal doxorubicin — the preferred first-line chemotherapy — is not guaranteed in Zimbabwe's public system. Drug shortages are a recurring problem.

Immunotherapy — pomalidomide and other newer agents being studied for KS — is not available in Zimbabwe.

KSHV viral load testing — useful for monitoring disease activity and treatment response — is not available in Zimbabwe's public system.

Comprehensive staging — full CT scanning, endoscopy, and bronchoalveolar lavage for pulmonary KS — is difficult to access outside Harare and Bulawayo.

Specialist oncology input — KS in the context of HIV requires coordinated management between oncology and infectious disease. Outside the main teaching hospitals, this coordination is difficult to achieve.

---

Kaposi Sarcoma Treatment in India: What Is Available for Zimbabwean Patients

India's leading cancer hospitals — particularly those with dedicated oncology and infectious disease departments — offer a complete KS treatment pathway that is not available in Zimbabwe.

Liposomal doxorubicin (Doxil/Caelyx): Available reliably and continuously. No drug shortage interruptions.

Paclitaxel for refractory KS: Available as second-line treatment with proper monitoring.

Comprehensive staging: Full CT body scan, upper and lower endoscopy, bronchoscopy where indicated — all accessible and coordinated within a single hospital system.

HIV/KS co-management: Major Indian cancer centres have infectious disease departments experienced in managing HIV-positive oncology patients. ART optimisation and cancer treatment are managed simultaneously, with both specialist teams communicating directly.

KSHV and HIV viral load monitoring: Full laboratory support for monitoring both conditions throughout treatment.

Immunotherapy access: For patients with refractory KS, access to emerging treatment options through compassionate use or clinical trial enrolment at select Indian centres.

Palliative radiotherapy: For symptomatic skin or lymph node lesions, available on working equipment with short waiting times.

Cost estimates for KS treatment in India:

Liposomal doxorubicin chemotherapy (per cycle): USD 600 – USD 1,200

Full staging CT scan: USD 300 – USD 600

Upper and lower endoscopy: USD 400 – USD 700

Inpatient admission for workup and first treatment: USD 1,500 – USD 3,000

Realistic total budget for initial KS assessment and first treatment course in India:

USD 5,000 – USD 10,000 including travel and accommodation

For patients with visceral KS requiring extended treatment, costs are higher — but ongoing treatment can be partially continued in Zimbabwe with guidance from the Indian treating team, reducing the need for prolonged stays abroad.

[Explore cancer treatment options in India for Zimbabwean patients →](https://treatcancerinindia.com/cancer-treatment-india-for-zimbabwe)

---

The HIV Conversation That Cannot Be Avoided

Kaposi sarcoma in Zimbabwe cannot be discussed honestly without discussing HIV. And discussing HIV in Zimbabwe still carries stigma — in families, in communities, in workplaces — that delays both HIV diagnosis and KS recognition.

A man who does not know his HIV status — or who knows it and has not disclosed it — may ignore the skin lesions that would prompt a clinician to immediately think KS. He may not seek care because doing so would require revealing an HIV status he has been concealing. He may tell himself the marks are nothing because investigating them would mean confronting a diagnosis he is not ready to face.

This stigma costs lives. Not because HIV makes KS inevitable — it does not — but because undisclosed, uncontrolled HIV is the primary driver of KS risk. A Zimbabwean man whose HIV is known, treated, and well-controlled is at significantly lower risk of developing KS than one who does not know his status or whose treatment has lapsed.

Know your HIV status. Testing is available, free, and confidential across Zimbabwe's health system. If you are HIV-positive, access treatment. If you are on treatment, stay on it — consistent ART is the single most powerful protection against KS development.

If you are HIV-positive and notice skin changes — new lesions, unusual pigmentation, lumps anywhere on your body — go to a clinic promptly and ask specifically about Kaposi sarcoma. Do not assume it is a skin infection. Do not treat it with pharmacy cream and wait. Go.

---

A Word on Children

Kaposi sarcoma in Zimbabwean children — particularly those who are HIV-positive or HIV-exposed — presents differently from adult KS. The dominant pattern is lymph node involvement rather than skin lesions, and this means it can be mistaken for other lymph node diseases, including tuberculosis and lymphoma.

Children with HIV who develop persistently enlarged lymph nodes — particularly if accompanied by fever, weight loss, or general ill health — should be evaluated for KS as part of the differential diagnosis.

Paediatric KS treatment in India, at hospitals with dedicated children's oncology units, is significantly more advanced than what is available in Zimbabwe's public paediatric system. Families with children affected by this disease should know that this option exists.

[Learn about blood cancer treatment in India for Zimbabwean patients →](https://treatcancerinindia.com/blood-cancer-treatment-india-for-zimbabwe)

---

What to Do Right Now

If you are living with HIV in Zimbabwe:

Know your CD4 count and viral load. Stay on ART consistently. Know what KS lesions look like. Act immediately if skin changes appear.

If you have noticed unexplained skin lesions:

See a healthcare provider within days, not weeks. Ask specifically whether Kaposi sarcoma is a possibility. Insist on a biopsy if the clinician is uncertain.

If you have already been diagnosed with KS:

Understand your stage. Confirm whether liposomal doxorubicin is available for your treatment. If it is not — if the drug is out of stock or unaffordable — know that India offers a structured pathway to receive it, along with comprehensive staging and co-management of your HIV.

If you are supporting a family member with KS:

Break the silence around the HIV connection. The shame that keeps men from seeking care for KS lesions is costing lives that treatment could save. A conversation within a family — honest, non-judgemental, focused on action — can be the difference between stage one and stage four.

Also relevant for Zimbabwean patients affected by cancer:

• [Cervical cancer treatment in India for Zimbabweans →](https://treatcancerinindia.com/cervical-cancer-treatment-india-for-zimbabwe)
• [Breast cancer treatment in India for Zimbabwean patients →](https://treatcancerinindia.com/breast-cancer-treatment-india-for-zimbabwe)
• [Prostate cancer treatment in India for Zimbabwean patients →](https://treatcancerinindia.com/prostate-cancer-treatment-india-for-zimbabwe)
• [Blood cancer treatment in India for Zimbabwean patients →](https://treatcancerinindia.com/blood-cancer-treatment-india-for-zimbabwe)

---

Blessing, Six Months Later

He started liposomal doxorubicin three weeks after diagnosis. His ART regimen was adjusted at the same time, and his viral load was confirmed undetectable within eight weeks.

At six months, his skin lesions had reduced significantly. The lesion near his jawline was almost invisible. His CD4 count was rising.

His oncologist told him that the response was good — that if he stayed on treatment and maintained his ART, the outlook was meaningful.

He tells his friends who are living with HIV to check their skin. To know what KS looks like. To go immediately if something appears that was not there before.

He is still a mechanic in Chitungwiza. He still goes to work. His hands still smell of engine oil at the end of the day.

He is alive because someone recognised what was on his legs. He wants every Zimbabwean living with HIV to have the same chance.

---

If you or a family member has been diagnosed with Kaposi sarcoma in Zimbabwe and needs guidance on treatment options — including access to liposomal doxorubicin, comprehensive staging, and coordinated HIV/cancer management in India — [our patient support team offers a free consultation](https://treatcancerinindia.com/cancer-treatment-india-for-zimbabwe). We support Zimbabwean patients from Harare, Bulawayo, Chitungwiza, Mutare, and across the country in accessing the care they need.